Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.